H. Lelièvre

发表

Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.

Daniel Birnbaum, D. Birnbaum, B. Delaval, 2005, Cancer research.

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Andy Z. X. Zhu, A. Rolfe, A. Kierzek, 2020, Clinical pharmacology and therapeutics.

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

B. Coiffier, H. Lelièvre, S. Depil, 2015, Investigational New Drugs.

Supplementary Figure S1

E. Solary, W. Vainchenker, N. Debili, 2012 .

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms

E. Solary, W. Vainchenker, N. Debili, 2013, Cell Death and Disease.

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

H. Lelièvre, B. Bossenmaier, V. Blanc, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts

H. Lelièvre, S. Depil, P. Busson, 2014, PloS one.

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

B. Fox, J. Dipersio, J. Wigginton, 2017 .

Myeloproliferative disorders: premalignant, stem cell, G1 diseases?

D. Birnbaum, B. Delaval, H. Lelièvre, 2006, Leukemia.

Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.

H. Lelièvre, S. Depil, Y. Vassetzky, 2016, Gene.

Myeloproliferative disorders: the centrosome connection

D. Birnbaum, B. Delaval, H. Lelièvre, 2005, Leukemia.

The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression

F. Bertucci, D. Birnbaum, P. Finetti, 2013, Clinical Cancer Research.

Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators

F. Bertucci, D. Birnbaum, P. Finetti, 2006, Leukemia.

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

S. Rutella, J. Dipersio, S. Warren, 2018, Blood.

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

C. Viero, J. Dipersio, J. Wigginton, 2018, Blood.

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

B. Fox, J. Dipersio, P. Moore, 2017 .

Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome

D. Birnbaum, V. Chevrier, A. Tassin, 2008, Molecular Cancer.